ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorEdwards Lifesciences

About this trial

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Failing aortic bioprosthetic valve demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency

Bioprosthetic valve size suitable for SAPIEN X4 THV

NYHA functional class ≥ II

Heart Team agrees the subject is at high or greater surgical risk

Disqualifiers

Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system

Failing valve has moderate or severe paravalvular regurgitation

Failing valve is unstable, rocking, or not structurally intact

Known severe patient-prosthesis mismatch or bioprosthetic valve with residual mean gradient > 20 mmHg at the end of the index procedure for implantation of the original valve

Trial design

Design model

Single group

Treatments tested in this trial

  • SAPIEN X4/X4S THV

    Device

    Implantation of the SAPIEN X4/X4S valve

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Transcatheter Aortic Valve Replacement (TAVR) - Surgical ValveExperimental treatment 1 intervention
Group B: Transcatheter Aortic Valve Replacement (TAVR) - THVExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Non-hierarchical composite of death and stroke

The number of patients that died or had a stroke

Time frame
1 year

Secondary outcomes

1

Kansas City Cardiomyopathy Questionnaire (KCCQ) score

The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

Time frame
30 days
2

KCCQ score

Time frame
1 year
3

New York Heart Association (NYHA) functional class

NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.

Time frame
30 days
4

NYHA functional class

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.